FOLR1 and breast carcinoma: Recent studies demonstrate that approximately 30% of breast cancers express folate receptor alpha (FRA) and suggest that as many as 70–80% of late-stage metastatic triple-negative breast cancer (TNBC) tumors express this receptor (Shannessy et al., 2012; Ginter et al., 2017).